Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research

Overview

Journal Drugs

Specialty Pharmacology

Date 2013 Mar 19

PMID 23504356

Citations 37

Authors

Cristan Farmer

Audrey Thurm

Paul Grant

Affiliations

Soon will be listed here.

Abstract

The current review covers extant literature on pharmacotherapy for core symptoms of autism. The core symptoms of autism include impairments in social interaction and communication, as well as the presence of restricted and repetitive behaviors. There are no known efficacious treatments for the core social symptoms, although effects on repetitive behaviors are indicated with some data. While studies of fenfluramine, secretin, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics. Newer lines of research, including cholinergic and glutamatergic agents and oxytocin, will be of considerable interest in the future. However, research on the treatment of core symptoms is plagued by limitations in study design, statistical power, and other issues inherent to the study of treatments for autism (e.g., heterogeneity of the disorder) that continue to prevent the elucidation of efficacious treatments.

Citing Articles

Gene expression differences in the olfactory bulb associated with differential social interactions and olfactory deficits in Pax6 heterozygous mice.

Daems C, Baz E, DHooge R, Callaerts-Vegh Z, Callaerts P Biol Open. 2025; 14(2).

PMID: 39902612 PMC: 11832127. DOI: 10.1242/bio.061647.

Patterns of Psychotropic Prescribing Practices in Autistic Children and Adolescents: An Australian Perspective of Two Cohorts Five Years Apart.

Baldes A, May T, Brignell A, Williams K Child Psychiatry Hum Dev. 2024; .

PMID: 38824199 DOI: 10.1007/s10578-024-01710-5.

Glucose transporter 1 deficiency, AMP-activated protein kinase activation and immune dysregulation in autism spectrum disorder: Novel biomarker sources for clinical diagnosis.

Al-Bishri W Saudi J Biol Sci. 2023; 30(12):103849.

PMID: 38020228 PMC: 10654234. DOI: 10.1016/j.sjbs.2023.103849.

Acetylcholinesterase inhibitors for autistic spectrum disorders.

Ure A, Cox G, Haslam R, Williams K Cochrane Database Syst Rev. 2023; 6:CD013851.

PMID: 37267443 PMC: 10233795. DOI: 10.1002/14651858.CD013851.pub2.

Oxytocin protective effects on zebrafish larvae models of autism-like spectrum disorder.

Rahmati-Holasoo H, Salek Maghsoudi A, Akbarzade M, Gholami M, Shadboorestan A, Vakhshiteh F Iran J Basic Med Sci. 2023; 26(3):316-325.

PMID: 36865037 PMC: 9922369. DOI: 10.22038/IJBMS.2023.68165.14889.

References

Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J . Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2009; 35(4):990-8. PMC: 2846602. DOI: 10.1038/npp.2009.202. View

Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld D . A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56(1):21-7. DOI: 10.1001/archpsyc.56.1.21. View

Aman M, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow K . Outcome measures for clinical drug trials in autism. CNS Spectr. 2004; 9(1):36-47. PMC: 4441220. DOI: 10.1017/s1092852900008348. View

McDougle C, Scahill L, Aman M, McCracken J, Tierney E, Davies M . Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005; 162(6):1142-8. DOI: 10.1176/appi.ajp.162.6.1142. View

Sherman J, Factor D, Swinson R, Darjes R . The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989; 19(4):533-43. DOI: 10.1007/BF02212856. View

Gordon C, State R, Nelson J, Hamburger S, Rapoport J . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993; 50(6):441-7. DOI: 10.1001/archpsyc.1993.01820180039004. View

Scott L, Dhillon S . Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007; 9(5):343-54. DOI: 10.2165/00148581-200709050-00006. View

Doyle R, Frazier J, Spencer T, Geller D, Biederman J, Wilens T . Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006; 9(3):543-9. DOI: 10.1177/1087054705284091. View

Cook E, Leventhal B . The serotonin system in autism. Curr Opin Pediatr. 1996; 8(4):348-54. DOI: 10.1097/00008480-199608000-00008. View

10.

Insel T . The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010; 65(6):768-79. PMC: 2847497. DOI: 10.1016/j.neuron.2010.03.005. View

11.

Scahill L, McDougle C, Williams S, Dimitropoulos A, Aman M, McCracken J . Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006; 45(9):1114-23. DOI: 10.1097/01.chi.0000220854.79144.e7. View

12.

Posey D, Erickson C, Stigler K, McDougle C . The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol. 2006; 16(1-2):181-6. DOI: 10.1089/cap.2006.16.181. View

13.

Doyle C, McDougle C . Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother. 2012; 13(11):1615-29. DOI: 10.1517/14656566.2012.674110. View

14.

Krueger D, Bear M . Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med. 2010; 62:411-29. PMC: 3100156. DOI: 10.1146/annurev-med-061109-134644. View

15.

Rimmele U, Hediger K, Heinrichs M, Klaver P . Oxytocin makes a face in memory familiar. J Neurosci. 2009; 29(1):38-42. PMC: 6664913. DOI: 10.1523/JNEUROSCI.4260-08.2009. View

16.

Marcus R, Owen R, Manos G, Mankoski R, Kamen L, McQuade R . Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011; 72(9):1270-6. DOI: 10.4088/JCP.09m05933. View

17.

Aman M, Singh N, Stewart A, Field C . The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985; 89(5):485-91. View

18.

Lord C, Risi S, Lambrecht L, Cook Jr E, Leventhal B, DiLavore P . The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000; 30(3):205-23. View

19.

Stigler K, Mullett J, Erickson C, Posey D, McDougle C . Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 2012; 223(2):237-45. DOI: 10.1007/s00213-012-2711-3. View

20.

Gelenberg A, Thase M, Meyer R, Goodwin F, Katz M, Kraemer H . The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2009; 69(10):1513-28. DOI: 10.4088/jcp.v69n1001. View